

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2018

DESPATCHED ON 30TH NOVEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A68; B8, B60; Cw7, Cw10; DR4, DR7; DQ2, DQ7

		Summary of Results														
		PBL				T-Cells				B-Cells						
Total tested	7	7	7	7	32	32	32	32	32	32	32	32	32			
Positive	0	0	0	0	2	2	1	1	8	11	2	1				
Negative	7	7	7	7	30	30	31	31	24	21	30	31				
NT	1	1	1	1	2	2	2	2	3	3	3	3				
% Positive	0.0%	0.0%	0.0%	0.0%	6.3%	6.3%	3.1%	3.1%	25.0%	34.4%	6.3%	3.1%				
% Negative	100.0%	100.0%	100.0%	100.0%	93.8%	93.8%	96.9%	96.9%	75.0%	65.6%	93.8%	96.9%				
		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed	Negative	Negative				
HLA Antibody Specificity (Defined By CDC)		Multi B7 B27	B7	DR3	Cw2	Multi B7 B27	B7	DR3	Cw2	Multi B7 B27	B7	DR3	Cw2			
		Without DTT				Without DTT				Without DTT						
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Delay in supply of clas II Dynabeads therefore reserved for urgent use PBL not tested due to insufficient material. Reaction strength only entered if above negative control.
11	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
12	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
20	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
24		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34		YES	YES					Negative	Positive	Negative	Negative	Positive	Positive	Positive	Negative	
38	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
41		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
42	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
51		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
54		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
58		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
117	YES			Negative	Negative	Negative	Negative									
136		YES						Negative	Negative	Negative	Negative					
145	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	YES			Negative	Negative	Negative	Negative									
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
311		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
315		YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
351		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
406		YES	YES													
411		YES	YES	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2018

DESPATCHED ON 30TH NOVEMBER 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0	0	0	0	0	0	0	0	0	0	0	80	80	70
11	-	-	-	-	-	-	-	-	NT	NT	NT	NT	95	98	-
12	NT	NT	NT	NT	15%	-	-	-	15%	15%	-	-	-	95	95
20	1	1	1	1					1	1	1	1	98	-	85
23					1	1	1	1	4	4	1	2	-	90	80
24					10	10	10	10	20	30	20	10	-	95	95
25					1	1	1	1	1	1	1	1	-	100	100
28					1	1	1	1	1	1	1	1	-	95	90
34					1	4	1	1	8	8	8	1	-	95	80
38	1	1	1	1	1	1	1	1	4	4	1	1	98	98	90
39					-	-	-	-	4	2	-	-	-	99	90
41					2-3	2-3	2-3	2-3	4-6	8-12	5-10	5-12	-	95	95
42	<10%	<10%	<10%	<10%					<10%	20-40%	<10%	<10%	95	-	90
45					1	1	1	1	1	4	1	1	-	99	85
51					2	0	0	0	4	4	0	0	-	-	-
54					11-20%	21-30%	11-20%	11-20%	51-60%	61-70%	21-30%	11-20%	-	95	95
58					5%	<5%	<5%	<5%	10%	10%	10%	10%	-	95	90
101					1	1	1	1	1	1	1	1	-	-	-
114					2	1	1	1	2	1	1	1	-	-	-
116					1	1	1	1	1-2	1-2	1-2	1-2	-	95	85
117	1	1	1	1									83	-	-
136					1	1	1	1					99	99	99
145					-	-	-	-	-	-	-	-	-	100	100
149	-	-	-	-									85	-	-
162					-	-	-	-	-	-	-	-	-	100	100
181					1	1	1	1	1	1	1	1	-	98	95
186					0	0	0	0	0	0	0	0	-	99	99
204					2	1	1	1	2	2	2	2	-	-	-
206					0	0	0	0	0	0	0	0	-	100	90
223					1	1	1	1	2	2	2	2	-	100	95
227													-	98	98
268					1	1	1	1	1	1	1	1	-	80	80
284					1	1	1	1	1	2	1	1	-	95	90
297					1	1	1	1	4	4	1	1	-	80	70
311					NT	NT	NT	NT	NT	NT	NT	NT	-	-	-
315					1	1	1	1	1	1	1	1	-	80	80
351					NT	NT	NT	NT	NT	NT	NT	NT			
406															
411					4	4	4	4	6	4	4	4	-	75	60

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2018

DESPATCHED ON 30TH NOVEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A68; B8, B60; Cw7, Cw10; DR4, DR7; DQ2, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
				6	6	6	6	28	28	28	28	29	29	29	29	
				0	0	0	0	2	1	1	2	2	1	1	1	
				6	6	6	6	26	27	27	26	27	28	28	28	
				1	1	1	1	3	3	3	3	4	4	4	4	
				0.0%	0.0%	0.0%	0.0%	7.1%	3.6%	3.6%	7.1%	6.9%	3.4%	3.4%	3.4%	
				100.0%	100.0%	100.0%	100.0%	92.9%	96.4%	96.4%	92.9%	93.1%	96.6%	96.6%	96.6%	
Consensus				Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)				Multi B7 B27	B7	DR3	Cw2	Multi B7 B27	B7	DR3	Cw2	Multi B7 B27	B7	DR3	Cw2	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Delay in supply of class II Dynabeads therefore reserved for urgent use PBL not tested due to insufficient material. Reaction strength only entered if above negative control.
11	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
12	YES	YES	YES	NT	NT	NT	NT	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
15	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
20	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
24	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
38	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
41	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
42	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
45	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
54	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
58	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
101	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
204	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Uninterpretable due to IgM control positive with DTT
315	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
351	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT due to low cell viability No results returned
406	YES	YES	YES	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	
411	YES	YES	YES	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2018

DESPATCHED ON 30TH NOVEMBER 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0	0	0	0	0	0	0	0	0	0	0	80	80	70
11	-	-	-	-	-	-	-	-	-	-	-	-	95	98	-
12	NT	NT	NT	NT	60%	-	15%	40%	-	-	-	-	-	95	95
15					0	0	0	0	0	0	0	0	-	99	99
20	1	1	1	1					1	1	1	1	98	-	85
24					10	10	10	10	20	20	20	20	-	95	95
25					1	1	1	1	1	1	1	1	-	100	100
28					1	1	1	1	1	1	1	1	-	95	90
34					1	1	1	1	6	1	1	1	-	95	80
38	1	1	1	1	1	1	1	1	1	1	1	1	98	98	90
39					-	-	-	-	-	-	-	-	-	99	90
41					2	2	2	2	10-20	9-20	10-20	9-15	-	95	95
42	<10%	<10%	<10%	<10%					<10%	<10%	<10%	<10%	95	-	90
45					1	1	1	1	1	1	1	1	-	99	85
51					NT	NT	NT	NT	NT	NT	NT	NT	-	-	-
54					0-10%	0-10%	0-10%	0-10%	0-10%	0-10%	0-10%	0-10%	-	95	95
58					<5%	<5%	<5%	<5%	10%	10%	10%	10%	-	95	90
101					1	1	1	1	1	1	1	1	-	-	-
114					1	1	1	1	1	1	1	1	-	-	-
116					1	1	1	1	1	1	2	1	-	95	85
149	-	-	-	-									85	-	-
162					-	-	-	-	-	-	-	-	-	100	100
181					1	1	1	1	1	1	1	1	-	98	95
186					0	0	0	0	0	0	0	0	-	99	99
204					1	1	1	1	2	2	2	2	-	-	-
206					0	0	0	0	0	0	0	0	-	100	90
227													-	98	98
268					1	1	1	1	1	1	1	1	-	80	80
284					1	1	1	1	1	1	1	1	-	95	90
297					1	1	1	1	1	1	1	1	-	80	70
311					NT	NT	NT	NT	NT	NT	NT	NT	-	-	-
315					1	1	1	1	1	1	1	1	-	80	80
351					NT	NT	NT	NT	NT	NT	NT	NT	-	-	-
406													-	-	-
411					6	4	4	4	6	4	4	4	-	75	60